Recurrent Lymphoepithelioma of the Nasopharynx Completed Phase Trials for Gefitinib (DB00317)

IndicationStatusPhase
DBCOND0029500 (Recurrent Lymphoepithelioma of the Nasopharynx)CompletedNot Available
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00068497Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung CancerTreatment